In-silico drug
discovery methods can help in identifying drug targets via
bioinformatics tools. In addition, the methods can also be used to analyze the target
structures for possible binding active sites. The use of computational methods
and computers have permeated all aspects of drug discovery and drug design. The
methods are facilitating the access of massive amounts of data generated and
transforming the extensive complex biological data into useful knowledge for
the drug discovery process. These computational tools offer the advantage of
delivering new drug candidates more quickly and at a lower cost.
According to the
market intelligence report published by BIS Research, the in-silico
drug discovery market is projected to grow at a significant CAGR of 12.92%,
during the forecast period, 2019-2029. The global
in-silico drug discovery market is undergoing a significant change with regard
to the advancements that have already taken place and are currently invading
the market space. Additionally, with the emergence of in-silico drug testing,
there is immense potential for these emerging sub-markets to continue to propel
the overall in-silico drug discovery market.
In-silico drug discovery brought massively
high throughput sequencing data for enabling a new era of drug-based research.
The development of software for drugs provides more opportunities for
researchers to use various applications in genomic fields. Human genetics underwent
a new paradigm of research and medical genomics by sequencing technologies
since the Human Genome Project. The trend initiated by in-silico-based drug
technologies in human genomics brought a new era of whole genomic sequencing by
enabling the building of human genomes databases and providing appropriate
human reference genomes.
The in-silico drug discovery comprises
three stages, which involve the identification or discovery of a therapeutic
target and eventually building a heterogeneous small molecule library to be
tested against it in phases such as pre-clinical and clinical trials. Further,
the development of a virtual screening protocol is initialized by either
docking of small molecules from the library or building these structures in the
active site by employing de novo design methods.
Target identification is the first process
in the drug discovery pipeline. Identification and validation of druggable
targets from among thousands of candidate macromolecules is still a challenge.
However, various technologies for addressing the targets have been developed
recently. Genomic and proteomic approaches are significant tools for target
identification.
The global in-silico drug discovery market
witnessed two significant acquisitions, from January 2016 to December 2019. All the
acquisitions were aimed at the expansion of the product portfolio by acquiring
diagnostics with promising growth potential. Also, these acquisitions were
intended to strengthen the existing product portfolio for improving the accuracy
and sensitivity of the in-silico test. Including the mergers and activities, 22
key developments and strategies were recorded during the time frame from
January 2016 to June 2019.
Comments
Post a Comment